Key facts
- Biologica’s last known valuation is $25.0M (Dec 2025).
- It has raised $7.0M; the latest was Seed Round ($7.0M) in Dec 2025.
- Notable investors include Greycroft, Hawktail, Addition, Good Friends, Gabrielle Bernstein — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Biologica
- ·The full record, as it builds
Funding rounds
No funding rounds for Biologica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biologica
Provider of personalized nutritional supplements designed for women's hormonal health across different life stages. The company's platform offers tailored formulations based on biological age, targeting key nutrient deficiencies and symptoms associated with hormonal changes, enabling women to support overall well-being through stage-specific daily supplementation.
- Sector
- Consumer Products and Services (B2C)
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- biologica.com/
- Ownership
- Privately Held (backing)
Biologica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biologica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biologica in its N-PORT filings yet. We sweep new filings monthly.